PEDIATRICS Vol. 117 No. 5 May 2006, pp. 1680-1687 (doi:10.1542/peds.2005-1996)
Changing Incidence of Candida Bloodstream Infections Among NICU Patients in the United States: 1995–2004
a Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases
c Health Outcomes Branch, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia
b Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia
OBJECTIVES. Recent reports suggest that candidemia caused by fluconazole-resistant strains is increasing in certain adult populations. We evaluated the annual incidence of neonatal candidemia and the frequency of disease caused by different species of Candida among neonates in the United States.
PATIENTS. The study included neonates admitted to 128 NICUs participating in the National Nosocomial Infections Surveillance system from January 1, 1995, to December 31, 2004 (study period).
METHODS. Reports of bloodstream infection (BSI) with Candida spp.; Candida BSIs, patient admissions, patient-days, and central venous catheter days were pooled by birth weight category. The number of Candida BSIs per 100 patients (attack rate) and per 1000 patient-days (incidence density) was determined. Both overall and species-specific rates were calculated; data were pooled over time to determine the differences by birth weight category and by year to determine trends over time.
RESULTS. From the 130523 patients admitted to NICUs during the study period, there were 1997 Candida spp. BSIs reported. Overall, 1472 occurred in the <1000-g birth weight group. Candida albicans BSIs were most common, followed by Candida parapsilosis, Candida tropicalis, Candida lusitaniae, Candida glabrata, and only 3 Candida krusei. Among neonates <1000 g, incidence per 1000 patient-days decreased from 3.51 during 1995–1999 to 2.68 during 2000–2004 but remained stable among heavier neonates. No increase in infections by species that tend to demonstrate resistance to fluconazole (C glabrata or C krusei) was observed.
CONCLUSIONS. Although Candida BSI is a serous problem among neonates <1000 g, incidence has declined over the past decade, and disease with species commonly resistant to azoles was extremely rare.
Key Words: Candida • intensive care units • hospital-acquired infection • fungemia • candidiasis • bloodstream infection • high-risk nursery • extremely low birth weight infant • neonatal
Abbreviations: BSI—bloodstream infection • NNIS—National Nosocomial Infections Surveillance • CVC—central venous catheter
Accepted Oct 31, 2005.
This article has been cited by other articles:
 |
|
 |
|
  M Brecht, L Clerihew, and W McGuire Prevention and treatment of invasive fungal infection in very low birthweight infants Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2009; 94(1): F65 - F69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Healy Fungal Prophylaxis in the Neonatal Intensive Care Unit NeoReviews, December 1, 2008; 9(12): e562 - e570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kaufman Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants Pediatrics, November 1, 2008; 122(5): 1158 - 1159. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Healy, J. R. Campbell, E. Zaccaria, and C. J. Baker Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species Pediatrics, April 1, 2008; 121(4): 703 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, K. P. Ng, A. Colombo, J. Finquelievich, R. Barnes, J. Wadula, and the Global Antifungal Surveillance Group Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 J. Clin. Microbiol., March 1, 2008; 46(3): 842 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ding and G. Butler Development of a Gene Knockout System in Candida parapsilosis Reveals a Conserved Role for BCR1 in Biofilm Formation Eukaryot. Cell, August 1, 2007; 6(8): 1310 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rossignol, M. E. Logue, K. Reynolds, M. Grenon, N. F. Lowndes, and G. Butler Transcriptional Response of Candida parapsilosis following Exposure to Farnesol Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2304 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manzoni, I. Stolfi, L. Pugni, L. Decembrino, C. Magnani, G. Vetrano, E. Tridapalli, G. Corona, C. Giovannozzi, D. Farina, et al. A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates N. Engl. J. Med., June 14, 2007; 356(24): 2483 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-K. Kim, K. E. Bissati, and C. B. Mamoun Amino acids mediate colony and cell differentiation in the fungal pathogen Candida parapsilosis. Microbiology, October 1, 2006; 152(Pt 10): 2885 - 2894. [Abstract] [Full Text] [PDF]
|
|
